Regulation of the viability of Nf1 deficient cells by PKC isoforms

Area of Science:

• Molecular oncology
• Cellular signaling
• Cancer biology

Background:

• Protein kinase C (PKC) inhibition is synthetically lethal with ras mutations in cancer.
• PKC blockade impacts the viability of neurofibromatosis type 1 (Nf1) deficient cells.
• The PKC family has over 10 isoforms, necessitating isoform-specific investigation.

Purpose of the Study:

• Identify specific PKC isoforms crucial for sensitizing Nf1-deficient cells to apoptosis.
• Investigate the role of PKC isoforms in Nf1-deficient cellular viability and apoptosis.
• Elucidate the signaling pathways involved in Nf1 deficiency-induced apoptosis.

Main Methods:

• Utilized genetic and chemical inhibitors targeting PKC isoforms.
• Compared apoptosis induction in Nf1-deficient cells versus normal or Nf1-expressing cells.
• Assessed protein expression, translocation (PKC δ), caspase activation (caspase 3 cleavage), and mitochondrial pathway involvement (cytochrome c release).

Main Results:

• Concurrent inhibition of PKC α and β induced apoptosis in Nf1-deficient ST or 96.2 cells.
• Apoptosis was not observed in SNF02.2 cells with normal Nf1 or ST cells expressing an Nf1 effective domain.
• PKC δ was upregulated and translocated to the nucleus in Nf1-deficient cells, correlating with caspase 3 cleavage and cytochrome c release.

Conclusions:

• PKC δ and the α/β isoforms are critical for sustaining aberrant Ras signaling and viability in Nf1-deficient cells.
• Inhibiting PKC α/β isoforms activates PKC δ, initiating the caspase 3-mediated apoptotic pathway.
• Targeting these specific PKC isoforms represents a potential therapeutic strategy for Nf1-related cancers.